Luyang Yao

551 total citations
12 papers, 117 citations indexed

About

Luyang Yao is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Luyang Yao has authored 12 papers receiving a total of 117 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Luyang Yao's work include Cancer Genomics and Diagnostics (5 papers), Cell death mechanisms and regulation (2 papers) and RNA modifications and cancer (2 papers). Luyang Yao is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Cell death mechanisms and regulation (2 papers) and RNA modifications and cancer (2 papers). Luyang Yao collaborates with scholars based in United States and China. Luyang Yao's co-authors include Jianxin Gu, Steven H. Lin, Jianhai Jiang, Anne S. Tsao, George R. Blumenschein, Daniel R. Gomez, John V. Heymach, Jun Yan, Chen Chen and Yuanyan Wei and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Luyang Yao

12 papers receiving 115 citations

Peers

Countries citing papers authored by Luyang Yao

Since Specialization

Citations

This map shows the geographic impact of Luyang Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luyang Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luyang Yao more than expected).

Fields of papers citing papers by Luyang Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luyang Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luyang Yao. The network helps show where Luyang Yao may publish in the future.

Co-authorship network of co-authors of Luyang Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Luyang Yao. A scholar is included among the top collaborators of Luyang Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luyang Yao. Luyang Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Network meta-analysis evaluating the impact of diverse exercise regimens on quality of life in women post-breast cancer surgery 2024 ·Medicine ·Luyang Yao, (unknown), Yuxin Yuan, Xiaofei Li, (unknown)	2
2	Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer 2023 ·Translational Lung Cancer Research ·Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, (unknown), (unknown), (unknown), (unknown), Wei Qiao, Suyu Liu, Luyang Yao, Steven H. Lin, James M. Reuben	6
3	Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial 2022 ·Lung Cancer ·Yufei Liu, Luyang Yao, Neda Kalhor, Brett W. Carter, Mehmet Altan, George R. Blumenschein, Lauren A. Byers, Frank V. Fossella, Don L. Gibbons, Jonathan M. Kurie, Charles Lu, Ferdinandos Skoulidis, Joe Y. Chang, Zhongxing Liao, Daniel R. Gomez, Michael S. O’Reilly, John V. Heymach, Anne S. Tsao, Steven H. Lin	21
4	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer 2022 ·Cancer Treatment and Research Communications ·Steven H. Lin, Heather Lin, Vivek Verma, Meng Xu‐Welliver, Peter F. Thall, Luyang Yao, Peter Kim, Dan S. Gombos, Jitesh D. Kawedia, Ritsuko Komaki, Daniel R. Gomez, Quynh‐Nhu Nguyen, Michael S. O’Reilly, Charles Lu, Frank V. Fossella, Ferdinandos Skoulidis, Jianjun Zhang, Anne S. Tsao, John V. Heymach, George R. Blumenschein	6
5	Abstract PO-069: Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer 2021 ·Clinical Cancer Research ·Everett J. Moding, Yufei Liu, Angela B. Hui, Jianzhong He, Yawei Qiao, Ting Xu, Luyang Yao, Saumil Gandhi, Zhongxing Liao, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn	2
6	Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients 2020 ·Translational Lung Cancer Research ·Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Wei Qiao, Suyu Liu, Jianzhong He, Yawei Qiao, Luyang Yao, (unknown), James M. Reuben	9
7	A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. 2020 ·Journal of Clinical Oncology ·Everett J. Moding, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, Yufei Liu, Jacob J. Chabon, Jianzhong He, Yawei Qiao, Ting Xu, Luyang Yao, Saumil Gandhi, Zhongxing Liao, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn	1
8	I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects. 2020 ·Journal of Clinical Oncology ·Joe Y. Chang, Steven H. Lin, Luyang Yao, Saumil Gandhi, Zhongxing Liao, Stephen G. Chun, Melenda Jeter, James W. Welsh, Percy Lee, Mara B. Antonoff, Lei Feng, J. Jack Lee, John V. Heymach	5
9	OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Steven H. Lin, Lin Xiao, Daniel L. Clay, Luyang Yao, (unknown), Daniel R. Gomez, Jonathan M. Kurie, George R. Simon, George R. Blumenschein, (unknown), S. Phan, A. Sandler, Vassiliki A. Papadimitrakopoulou, John V. Heymach, Anne S. Tsao	20
10	CDK11p58 protein kinase activity is associated with Bcl-2 down-regulation in pro-apoptosis pathway 2007 ·Molecular and Cellular Biochemistry ·Xiaojing Yun, (unknown), Luyang Yao, Hongliang Zong, Yi Hong, Jianhai Jiang, (unknown), Zhou Zhang, Jianxin Gu	15
11	Induction of apoptosis by p110C requires mitochondrial translocation of the proapoptotic BCL‐2 family member BAD 2006 ·FEBS Letters ·Chen Chen, Jun Yan, Qing Sun, Luyang Yao, (unknown), (unknown), Jianxin Gu	15
12	Identification of extracellular signal-regulated kinase 3 as a new interaction partner of cyclin D3 2005 ·Biochemical and Biophysical Research Communications ·Maoyun Sun, Yuanyan Wei, Luyang Yao, Jianhui Xie, Xiaoning Chen, Hanzhou Wang, Jianhai Jiang, Jianxin Gu	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact